The nice people at the Transfusion Evidence Library sent their update today. They do sent a lot… too much for my poor brain to take in at one go… but very welcome nonetheless…
Top Article
Selected Articles
Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy.Balitsky, A.K., et al. (2021). Transfusion.
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.Bohlius, J., et al. (2019). Blood Advances.
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.Estcourt, L.J., et al. (2017). The Cochrane Database of Systematic Reviews.
Development and validation of a nomogram to predict intraoperative blood transfusion for gastric cancer surgery.Huang, H., and Cao, M., (2021). Transfusion Medicine.
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD). Makharadze, T., et al. (2021). American Journal of Hematology.
Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis.Petrelli, F., et al. (2021). Surgery Today.
Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial.Tay, J., et al. (2020). Journal of Clinical Oncology
Preoperative tranexamic acid does not reduce transfusion rates in major oncologic surgery: Results of a randomized, double-blind, and placebo-controlled trial.Wright, G.P., et al. (2020). Journal of Surgical Oncology.
Restrictive versus liberal transfusion strategies in patients with malignant neoplasm -a meta-analysis of randomized controlled trials.Yang, X.X., et al. (2020). Transfusion and Apheresis Science.
No comments:
Post a Comment